Lilly Wins Stay In Zyprexa Whistleblower Suit
In a boost to Eli Lilly & Co., a federal judge has granted the pharmaceutical giant's bid to stay a whistleblower suit over charges it marketed its blockbuster anti-psychotic drug Zyprexa...To view the full article, register now.
Already a subscriber? Click here to view full article